Anavex Life Sciences Corp. logo

Anavex Life Sciences Corp.

NASDAQ:AVXL

Overview | Financials
Company Name Anavex Life Sciences Corp.
Symbol AVXL
Currency USD
Price 5.15
Market Cap 436,696,825
Dividend Yield 0%
52-week-range 3.25 - 10.45
Industry Biotechnology
Sector Healthcare
CEO Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
Website https://www.anavex.com

An error occurred while fetching data.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to

Related Stocks

Alector, Inc. logo

Alector, Inc.

ALEC

4.85 USD

DocGo Inc. logo

DocGo Inc.

DCGO

3.63 USD

TG Therapeutics, Inc. logo

TG Therapeutics, Inc.

TGTX

22.03 USD

Organogenesis Holdings Inc. logo

Organogenesis Holdings Inc.

ORGO

2.47 USD

IGM Biosciences, Inc. logo

IGM Biosciences, Inc.

IGMS

9.31 USD

NanoString Technologies, Inc. logo

NanoString Technologies, Inc.

NSTG

0.105 USD

Catalyst Pharmaceuticals, Inc. logo

Catalyst Pharmaceuticals, Inc.

CPRX

19.6 USD

Deciphera Pharmaceuticals, Inc. logo

Deciphera Pharmaceuticals, Inc.

DCPH

25.59 USD

Financials

Numbers are in millions USD

Numbers are in millions USD